"Circulating Tumor DNA" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA released from tumor cells that is found circulating in PLASMA; SERUM; or other BODY FLUIDS.
| Descriptor ID |
D000074141
|
| MeSH Number(s) |
D13.444.154.500 D13.444.308.425.500
|
| Concept/Terms |
Circulating Tumor DNA- Circulating Tumor DNA
- DNA, Circulating Tumor
- Tumor DNA, Circulating
- Cell-Free Tumor DNA
- Cell Free Tumor DNA
- DNA, Cell-Free Tumor
- Tumor DNA, Cell-Free
|
Below are MeSH descriptors whose meaning is more general than "Circulating Tumor DNA".
Below are MeSH descriptors whose meaning is more specific than "Circulating Tumor DNA".
This graph shows the total number of publications written about "Circulating Tumor DNA" by people in this website by year, and whether "Circulating Tumor DNA" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 5 | 1 | 6 |
| 2018 | 12 | 0 | 12 |
| 2019 | 12 | 4 | 16 |
| 2020 | 10 | 1 | 11 |
| 2021 | 16 | 1 | 17 |
| 2022 | 19 | 0 | 19 |
| 2023 | 13 | 0 | 13 |
| 2024 | 10 | 3 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Circulating Tumor DNA" by people in Profiles.
-
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. JCO Precis Oncol. 2024 Dec; 8:e2400288.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25; 15(1):10213.
-
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer. Cancer Cell. 2024 Sep 09; 42(9):1598-1613.e4.
-
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer. 2024 Aug 16; 24(1):1016.
-
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer. Eur J Cancer. 2024 Oct; 210:114257.
-
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2024 Jul 09; 15(1):5763.
-
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2444-2451.
-
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 May; 8:e2300531.
-
Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy. Adv Anat Pathol. 2024 Sep 01; 31(5):324-332.
-
Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2024 Apr 04; 29(4):e475-e486.